Stockscreener 앱 받기
5.2788
3.94%
0.2088
전일 마감가:
$5.07
열려 있는:
$5.07
하루 거래량:
222.24K
Relative Volume:
5.00
시가총액:
$411.68M
수익:
$163.13M
순이익/손실:
$-34.75M
주가수익비율:
-10.25
EPS:
-0.5152
순현금흐름:
$-231.66M
1주 성능:
+11.18%
1개월 성능:
+21.99%
6개월 성능:
-26.81%
1년 성능:
-35.34%
1일 변동 폭
$4.96
$5.3397
1주일 범위
$4.71
$5.3397
52주 변동 폭
$3.62
$9.50
발네바 Stock (VALN) Company Profile
VALN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
5.24 | 411.68M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.82 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.39 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.38 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.34 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.02 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
발네바 Stock (VALN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-03 | 개시 | H.C. Wainwright | Buy |
발네바 주식(VALN)의 최신 뉴스
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - GlobeNewswire Inc.
VALNEVA - GlobeNewswire Inc.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock - Yahoo Finance
Valneva SE earnings missed by $0.02, revenue fell short of estimates - Investing.com
Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target - Investing.com
Valneva SE Declaration of shares and voting rights - GlobeNewswire Inc.
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy - Investing.com
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy By Investing.com - Investing.com South Africa
In-Depth Examination Of 6 Analyst Recommendations For Valneva - Benzinga
Valneva shares hold strong with buy rating on Lyme vaccine data - Investing.com
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know - MSN
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock - Zacks Investment Research
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3% - Yahoo Finance
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine - Zacks Investment Research
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval - Yahoo Finance
Earnings call: Valneva reports robust growth and strategic R&D focus By Investing.com - Investing.com South Africa
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Nasdaq
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why - Yahoo Finance
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe - Zacks Investment Research
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal - Yahoo Finance
5 Top Health Care Stocks To Watch In The Stock Market Today - Stock Market
Valneva Stock Is Jumping on European Vaccine Supply Deal - Barron's
Valneva Stock Surges After EU Vaccine Deal - Investing.com
Valneva Shares Off 12% On Share Offering News By Investing.com - Investing.com UK
Valneva (VALN) Reports Positive Data From COVID Vaccine Study - Nasdaq
Valneva Stock Plunges as U.K. Drops Covid-19 Vaccine Deal - Barron's
EU set to sign off new Pfizer vaccine contract as soon as Friday - Luxembourg Times
Shareholder Structure - Valneva
Stock Price - Valneva
발네바 (VALN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):